Top

BMC Cancer

Published in:

Open Access 01-12-2017 | Research article

Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance

Authors: Xinsa Fu, Congxiang Shen, Huigang Wang, Fang Chen, Guanxue Li, Zhong Wen

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

The study was aimed to quantitatively detect mRNA levels of the catalytic subunit of telomerase (hTERT) in both peripheral blood and circulating tumor cells (CTCs) of patients with nasopharyngeal carcinoma (NPC) and explore its significance in early diagnosis and treatment of NPC.

Methods

hTERT mRNA levels in peripheral blood and CTCs of 33 NPC patients before and after treatment with intensity-modulated radiation therapy (IMRT) or/and chemotherapy and 24 healthy controls were measured using real-time quantitative PCR (qPCR) and their correlations to clinic pathological factors of NPC were analyzed.

Results

Peripheral hTERT mRNA content was 10.75 ± 4.29 in NPC patients and 0.95 ± 0.37 in control subjects (P < 0.05), and had a significant correlation with patients’ clinical stage, T stage, and N stage (P < 0.05). Treatment of NPC patients at stages I and II with simple IMRT significantly reduced hTERT mRNA level from 5.60 ± 2.33 to 3.43 ± 1.42 (P < 0.05) and treatment of patients at advanced stage (III and IV) with induction chemotherapy followed by IMRT significantly reduced hTERT mRNA levels from 12.68 ± 3.08 to 10.68 ± 2.48 to 3.13 ± 1.69 (P < 0.05), respectively. In addition, the study also showed that hTERT mRNA content in CTCs of NPC patients was 10.65 ± 4.28, evidently higher than that of 1.09 ± 0.40 in control subjects (P < 0.05) and hTERT mRNA level in CTCs of NPC patients was obviously correlated to patients’ clinical stage, T stage and N stage (P < 0.05). After treatment, hTERT mRNA level in CTCs of NPC patients lowered from 10.65 ± 4.28 to 5.59 ± 2.32 (P < 0.05). The correlation analysis found that hTERT mRNA level in peripheral blood and CTCs of NPC patients were highly correlated with a correlation coefficient of 0.981.

Conclusions

hTERT mRNA levels in peripheral blood and CTCs of NPC patients were significantly enhanced compared to that in healthy controls and highly correlated. Changes in hTERT mRNA level was closely correlated to patients’ clinical stage and T stage. Radiochemotherapy could effectively reduce hTERT mRNA level in peripheral blood and CTCs. Thus, it is possible using the joint detection of hTERT mRNA level in peripheral blood and CTCs as a new biomarker for early diagnosis, treatment efficacy and prognosis of NPC.

Bhattacharyya N. The impact of race on survivalin nasopharyngeal carcinoma: a matched analysis. Am J Otolaryngol. 2004;25(2):94–7.CrossRefPubMed

McDermott AL, Dutt SN, Watkinson JC. The etiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 2001;26(2):82–92.CrossRefPubMed

He Y, Cai Q, Huang C, Hong S. Survival statistics of 3028 cases of nasopharyngeal cancer. China Med Rec. 2008;9(3):38–9.

Dasi F, Martínez-Rodes P, March JA, Santamaria J, Martinez-Javaloyas JM, Gil M, Alino SF. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann N Y Acad Sci. 2006;1075(1):204–10.CrossRefPubMed

Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, Takahashi S, Adachi Y, Shomori K, Sano A, Kishimoto Y, Ito H, Hasegawa J, Shito G. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci. 2006;97(12):1366–73.CrossRefPubMed

Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37.CrossRefPubMed

Kang Y, Zhang J, Sun P, Shang J. Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer. Int J Clin Oncol. 2013;18(3):478–86.CrossRefPubMed

Cheng M, Liu L, Yang HS, Liu GF. Circulating tumor cells are associated with bone metastasis of lung cancer. Asian Pac J Cancer Prev. 2014;15(15):6369–74.CrossRefPubMed

Man Y, Cao J, Jin S, Xu G, Pan B, Shang L, Che D, Yu Q, Yu Y. Newly identified biomarkers for detecting circulating tumor cells in lung adenocarcinoma. Tohoku J Exp Med. 2014;234(1):29–40.CrossRefPubMed

10.

Wang H, Ahn S, Kim S, Park S, Park S, Han H, Sohn JH, Kin S, Lee H. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. Exp Mol Pathol. 2014;97(3):445–52.CrossRefPubMed

11.

Liu D, Xia W, Tang Q, Wang J, Wang M, Wang Y, Wang S, Ye Y, Zhou W, Shao Y. Detection of pelvic lymph node micrometastasis by real time reverse transcriptase polymerase chain reaction in prostate cancer patients after hormonal therapy. J Cancer Res Clin Oncol. 2014;140(2):235–41.CrossRefPubMed

12.

Wen Z, Xiao JY, Tang FQ, Tian YQ, Zhao SP, Chen BL. The expression of telomerase and its RNA in nasopharyngeal carcinoma. J Chin Med. 2000;113(6):525–8.

13.

Wen Z, Xiao JY, Tian YQ, Chen BL. Down-regulation of telomerase and its RNA and apoptosis in HNE1 cell lines of nasopharyngeal carcinama induced by hTR anti-sense oligonucleotide. Int J Modern Cancer Therapy. 2000;3(1):77–81.

14.

Shen CX, Wen Z, Qian YH, Mu SF, Guan XF. Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer. J Exp Clin Canc Res. 2010;29(1):94.CrossRef

15.

Lang J. 2008 symposium of China nasopharyngeal carcinoma. Guangzhou Cancer Prev Treat. 2009;22(1):115–6.

16.

Zhang X, Cheng R, Shi Z, Jin Y. A PCR-free fluorescence strategy for detecting telomerase activity via double amplification strategy. Biosens Bioelectron. 2016;75:101–7.CrossRefPubMed

17.

Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, Noma E, Sakaguchi S, Nagashima M, Kudo M, Kishimoto Y, Kawasaki H, Hasegawa J, Shita G. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology. 2007;72(Suppl 1):45–51.CrossRefPubMed

18.

March-Villalba JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaria J, Alino SF, Dasi F. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients. Expert Opin Biol Ther. 2012;12(Suppl 1):S69–77.CrossRefPubMed

19.

March-Villalba JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaria J, Alino SF, Dasi F. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS One. 2012;7(8):e43470.CrossRefPubMedPubMedCentral

20.

El-Mazny A, Sayed M, Sharaf S. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma. Arab J Gastroenterol. 2014;15(2):68–71.CrossRefPubMed

21.

Perhavec A, Cerkovnik P, Novaskovic S, Zgajnar J. The hTERT mRNA in plasma samples of early breast cancer patients, non-cancer patients and healthy individuals. Neoplasma. 2008;55(6):549–54.PubMed

22.

Pelosi G, Schianchi E, Dell’Orto P, Veronesi G, Spaggiari L, Pashi F, Sozzi G, Brambilla E, Griso C, Viale G. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. Virchows Arch. 2006;448(1):7–15.CrossRefPubMed

23.

Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G, DelBianco P, Nitti D, DeRossi A. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res. 2008;14(22):7444–51.CrossRefPubMed

24.

Ping B, Tsuno S, Wang X, Ishihara Y, Yamashita T, Miura K, Miyoshi F, Shinohara Y, Matsuki T, Tanabe Y, Tanaka N, Ogawa T, Shiota G, Miura N. Comparative study of ¹⁸F-FDG-PET/CT imaging and serum hTERT mRNA quantification in cancer diagnosis. Cancer Med. 2015;4(10):1603–11.CrossRefPubMedPubMedCentral

25.

Pucciarelli S, Rampazzo E, Briarava M, Maretto I, Agostini M, Digito M, Keppel S, Friso ML, Lonardi S, De Paoli A, Mescoli C, Nitti D, De Rossi A. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor responsein rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2012;19(2):3089–96.CrossRefPubMed

26.

Lu J, Li J, Chen F, Zhou Z. Quantification of plasma hTERT mRNA in patients with AML and laryngeal squamous cell carcinoma and its clinical significance. J Mol Diagn Ther. 2009;1(4):222–6.

27.

Wei J. Situation of combined chemotherapy and radiotherapy of nasopharyngeal carcinoma. J Pract Oncol. 2014;29(3):294–8.

28.

Andergassen U, Zebisch M, Kölbl AC, König A, Heublein S, Schröder L, Hutter S, Friese K, Jeschke U. Real-time qPCR-based detection of circulating tumor cells from blood samples of adjuvant breast cancer patients: a preliminary study. Breast Care (Basel). 2016;11(3):194–8.CrossRef

29.

Vaiopoulos AG, Kostakis ID, Gkioka E, Athanasoula KC, Pikoulis E, Papalambros A, Christopoulos PF, Gogas H, Kouraklis G, Koutsilieris M. Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Res. 2014;34(6):3083–92.PubMed

30.

Li S, Zhao B, Zhang J, He KZ. The research progress of nasopharyngeal carcinoma with distal metastasis. Med Recapitulate. 2014;20(6):1020–2.

Title: Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance
Authors: Xinsa Fu
Congxiang Shen
Huigang Wang
Fang Chen
Guanxue Li
Zhong Wen
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3471-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma

Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation

Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas

Design of a randomized controlled trial of physical training and cancer (Phys-Can) – the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome

Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years

Keynote webinar | Spotlight on antibody–drug conjugates in cancer